- List Biotherapeutics and Sacco System have announced a lead share agreement. The agreement aims to mutually recommend each other’s microbial development and manufacturing services.
List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) have announced a lead share agreement. The agreement is designed to introduce and mutually recommend each other’s microbial development and manufacturing services to prospective customers if one party discovers a project that is better suited to the other party’s capability or capacity.
The companies will not exchange any intellectual property. Instead, they will leverage their respective strengths. Sacco System specialises in the development and production of probiotics, postbiotics, and live bacterial therapeutics for the agri-food, food supplements, and pharmaceutical industry. List Bio and its sister company, List Labs, specialise in the development and production of innovative bacterial-based therapeutic products.
“This lead share agreement will help us meet the diverse global needs of microbiome therapeutics development and commercialization in a thriving market, where over 100 companies are actively developing more than 240 microbiome modulator candidates,” said List Bio President and CEO Jonathan Jo. “We are delighted to expand List Labs and List Bio’s integrated cGMP pharma grade anaerobic and spore forming microbe production capabilities to biotherapeutic developers in Europe and the Asia Pacific region through Sacco’ System’s strong client base.”
Sacco System Australia Managing Director John Goebel said, “Sacco looks forward to offering our large-scale fermentation capabilities to any List Bio or List Labs biotherapeutics clients who wish to manufacture probiotics and LBPs in large volume. We are confident that this will be the first of many future strategic alliances as the microbiome market continues to grow.”
Overview of outsourcing trends 
